[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Flanagan KH, Brennan DC: EBV-associated recurrent Hodgkin's disease after renal transplantation. Transpl Int; 2006 Apr;19(4):338-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-associated recurrent Hodgkin's disease after renal transplantation.
  • Hodgkin's disease is recognized as part of the spectrum of post-transplantation lymphoproliferative disorders (PTLD), although it is still an uncommon de novo malignancy in this population.
  • Epstein-Barr virus (EBV) has been linked to both post-transplant non-Hodgkin's lymphomas and Hodgkin's disease.
  • We report a case of recurrent Hodgkin's disease in a patient who received a renal transplant in childhood and later developed EBV-associated Hodgkin's disease with remission after chemotherapy until subsequent relapse 9 years later that was successfully treated.
  • To our knowledge, this is the first report of recurrent Hodgkin's disease in a transplant recipient.
  • [MeSH-major] Epstein-Barr Virus Infections / etiology. Hodgkin Disease / etiology. Kidney Transplantation / adverse effects
  • [MeSH-minor] Adult. Herpesvirus 4, Human / isolation & purification. Humans. Kidney Failure, Chronic / surgery. Lymphoproliferative Disorders / etiology. Lymphoproliferative Disorders / therapy. Male. Recurrence. Risk Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1990 Jul;137(1):13-8 [2164775.001]
  • [Cites] Clin Infect Dis. 2004 Oct 1;39(7):1016-23 [15472855.001]
  • [Cites] Pediatr Transplant. 2004 Feb;8(1):87-90 [15009846.001]
  • [Cites] Am J Transplant. 2001 Jul;1(2):103-8 [12099356.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4472-80 [12907620.001]
  • [Cites] N Engl J Med. 1990 Dec 20;323(25):1723-8 [2100991.001]
  • [Cites] Lancet. 1991 Feb 9;337(8737):320-2 [1671232.001]
  • [Cites] Transplantation. 1997 Sep 27;64(6):848-52 [9326409.001]
  • [Cites] Curr Biol. 1998 Mar 12;8(6):R196-8 [9512412.001]
  • [Cites] J Heart Lung Transplant. 1998 Dec;17(12):1161-6 [9883755.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):191-6 [15621801.001]
  • [Cites] Transpl Int. 2005 Jun;18(6):643-50 [15910287.001]
  • [Cites] Transpl Int. 2004 Feb;17(2):89-96 [14652716.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2592-8 [11895798.001]
  • (PMID = 16573551.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC1448701
  •  go-up   go-down


2. Munshi A, Pandey MB, Kumar L, Karak AK, Mohanti BK: A case of Hodgkin's disease presenting with recurrent laryngeal nerve palsy and tracheoesophageal fistula. Med J Malaysia; 2006 Mar;61(1):97-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Hodgkin's disease presenting with recurrent laryngeal nerve palsy and tracheoesophageal fistula.
  • Hodgkins disease rarely leads to such a fistula.
  • We report a case of Hodgkin's disease with a tracheoesophageal fistula as well as a left recurrent nerve palsy at presentation.
  • On follow up 1 year after the completion of treatment, he was clinically and radiologically disease free.
  • [MeSH-major] Hodgkin Disease / diagnosis. Recurrent Laryngeal Nerve / pathology. Tracheoesophageal Fistula / diagnosis. Vocal Cord Paralysis / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Recurrence

  • Genetic Alliance. consumer health - Tracheoesophageal fistula.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708743.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


3. Cole PD, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett TM: Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol; 2009 Mar 20;27(9):1456-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.
  • PURPOSE: The Children's Oncology Group conducted this phase II study to assess the efficacy and toxicity of gemcitabine and vinorelbine (GV) in pediatric patients with heavily pretreated relapsed/refractory Hodgkin's disease.
  • CONCLUSION: GV is an effective and well-tolerated reinduction regimen for children with relapsed or refractory Hodgkin's disease.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2000 Apr;11(4):495-6 [10847474.001]
  • [Cites] Intern Med J. 2007 Nov;37(11):760-6 [17542998.001]
  • [Cites] Anticancer Drugs. 1999 Jul;10(6):525-31 [10885899.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2529-36 [10893283.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):573-6 [10944594.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):763-8 [10951338.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):707-14 [10952772.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):873-5 [10997817.001]
  • [Cites] Haematologica. 2000 Sep;85(9):926-9 [10980630.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):993-8 [11038036.001]
  • [Cites] Lung Cancer. 2001 Feb-Mar;31(2-3):277-84 [11165408.001]
  • [Cites] Oncologist. 2001;6 Suppl 1:16-9 [11182000.001]
  • [Cites] Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):15-7 [11252883.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):583-90 [11290433.001]
  • [Cites] Invest New Drugs. 2001;19(1):101-4 [11291828.001]
  • [Cites] Oncologist. 2001;6(2):153-61 [11306727.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3483-9 [11481354.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):830-5 [11550154.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Aug;48(2):151-9 [11561781.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):37-41 [11773151.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Jan;29(1):107-9 [11816464.001]
  • [Cites] Invest New Drugs. 2002 Feb;20(1):73-82 [12003196.001]
  • [Cites] Breast J. 2002 May-Jun;8(3):171-6 [12047474.001]
  • [Cites] Clin Breast Cancer. 2002 May;3 Suppl 1:34-8 [12057044.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):340-53 [12124835.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12):1862-7 [12453853.001]
  • [Cites] Gan To Kagaku Ryoho. 2003 Apr;30(4):515-7 [12722684.001]
  • [Cites] Clin Breast Cancer. 2003 Apr;4(1):46-50 [12744758.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):421-2 [14599876.001]
  • [Cites] Cancer. 2004 May 1;100(9):1793-9 [15112258.001]
  • [Cites] Pediatr Hematol Oncol. 2004 Mar;21(2):107-13 [15160509.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2348-56 [15197195.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):556-61 [3559649.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Cancer. 1999 Oct 15;86(8):1463-9 [10526274.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):405-11 [10637256.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):557-62 [10649247.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Lung Cancer. 2000 Jan;27(1):47-53 [10672783.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;27(4):258-62 [1998982.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):491-8 [1999720.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):406-13 [1740680.001]
  • [Cites] Ann Oncol. 1994 Nov;5(9):817-20 [7531487.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10 [7481842.001]
  • [Cites] Leuk Lymphoma. 1996 Aug;22(5-6):409-14 [8882953.001]
  • [Cites] Invest New Drugs. 1997;15(2):115-21 [9220290.001]
  • [Cites] Anticancer Drugs. 1998 Mar;9(3):191-201 [9625429.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):195-208 [9720729.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1003-8 [9818075.001]
  • [Cites] Hematol Oncol. 1998 Sep;16(3):101-5 [10235068.001]
  • [Cites] Anticancer Drugs. 1999 Aug;10(7):625-31 [10507311.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4532-40 [15542804.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):141-5 [16007883.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1473-8 [15870180.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1313-20 [16109609.001]
  • [Cites] Anticancer Drugs. 2006 Jan;17(1):107-11 [16317298.001]
  • [Cites] JOP. 2006;7(3):306-10 [16685112.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Strahlenther Onkol. 2007 Apr;183(4):215-7 [17406804.001]
  • [Cites] Chest. 2000 Jun;117(6):1583-9 [10858387.001]
  • (PMID = 19224841.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA98543
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC2668553
  •  go-up   go-down


Advertisement
4. Sheehy N, Israel DA: Acute varicella infection mimics recurrent Hodgkin's disease on F-18 FDG PET/CT. Clin Nucl Med; 2007 Oct;32(10):820-1
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute varicella infection mimics recurrent Hodgkin's disease on F-18 FDG PET/CT.
  • We report a case where acute varicella infection, chickenpox, mimics the findings of recurrent Hodgkin disease on F-18 FDG PET/CT.
  • A 28-year-old man with a history of Hodgkin disease in remission had fatigue, pyrexia, and a raised ESR.
  • His F-18 FDG PET/CT, performed to exclude lymphoma recurrence, demonstrated FDG-avid lymphadenopathy and increased FDG uptake in his spleen.
  • Repeat F-18 FDG PET/CT done 1 month later showed no evidence of FDG-avid disease.
  • In this patient the stimulation of an immune response by the acute viral infection mimics recurrent lymphoma.
  • [MeSH-major] Chickenpox / diagnosis. Fluorodeoxyglucose F18. Hodgkin Disease / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Positron-Emission Tomography / methods. Radiopharmaceuticals. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Chickenpox.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885370.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


5. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG: Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol; 2009 Sep 10;27(26):4371-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
  • PURPOSE: To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics, and antitumor activity of dacetuzumab in patients with refractory or recurrent B-cell non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: In this open-label, dose-escalation phase I study, dacetuzumab was administered to six cohorts of adult patients.
  • AEs grade >or= 3 occurred in 30% of patients and included disease progression, anemia, pleural effusion, and thrombocytopenia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD40 / immunology. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / chemically induced. Antibodies, Monoclonal, Humanized. Cohort Studies. Cytokines / blood. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Fever / chemically induced. Headache / chemically induced. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Male. Middle Aged. Recurrence. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19636010.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00103779
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD40; 0 / Cytokines; 0 / dacetuzumab
  •  go-up   go-down


6. Introcaso CE, Kantor J, Porter DL, Junkins-Hopkins JM: Cutaneous Hodgkin's disease. J Am Acad Dermatol; 2008 Feb;58(2):295-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous Hodgkin's disease.
  • Cutaneous Hodgkin's disease is a rare condition that usually occurs late in the course of Hodgkin's lymphoma.
  • This rare condition is thought to have decreased in incidence in recent decades, likely owing to improved treatment of patients with Hodgkin's disease, who are receiving improved chemotherapy and radiation therapy, and the advent of peripheral blood stem cell transplantation.
  • We present the case of a man who developed specific cutaneous Hodgkin's lymphoma 6 months after nonmyeloablative allogenic stem cell transplantation for his recurrent systemic disease.
  • At the time of the cutaneous relapse he had minimal systemic disease.
  • This case illustrates an example of this complication of Hodgkin's disease and stresses the importance of a timely diagnosis to direct appropriate therapy.
  • A review of the literature demonstrates that the patient's lesion morphology and distribution are typical of specific manifestations of cutaneous Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / complications. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Erythema / etiology. Erythema / pathology. Graft vs Tumor Effect. Humans. Male. Recurrence. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222326.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


7. Kim HC, Nam SW, Cho YK, Jeong HJ, Kim SI, Kim SH, An CM, Kim IH, Kim SW, Lee SO, Lee ST: [A case of Non-Hodgkin's lymphoma in a patient with Crohn's disease]. Korean J Gastroenterol; 2006 Mar;47(3):233-7
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Non-Hodgkin's lymphoma in a patient with Crohn's disease].
  • Although adenocarcinoma is a well known complication of chronic inflammatory bowel disease, primary gastrointestinal lymphoma occurring in Crohn's disease is rare.
  • A 40-year-old man with 10 year-history of Crohn's disease had multiple longitudinal ulcerative lesions on descending colon in follow-up colonoscopic examination.
  • Microscopic examination of proximal descending colon revealed peripheral T cell lymphoma and other site of the descending colon was consistent with Crohn's disease.
  • The patient reached complete remission of malignant lymphoma after three cycles of combined chemotherapy.
  • Right hemicolectomy was done, but the patient died of post-surgical recurrent mesenteric abscess and sepsis.
  • To the best of our knowledge, this is the first case of Non-Hodgkin's lymphoma complicating Crohn's disease in Korea which was confirmed by immunohistochemical studies.
  • [MeSH-major] Colonic Neoplasms / complications. Crohn Disease / complications. Lymphoma, T-Cell / complications
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554679.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


8. Prior JO, Duchosal MA, Schmidt S, Turini P, Pilon N, Chioléro R, Pascual M: Absence of residual Hodgkin's disease demonstrated by PET/CT in a deceased organ donor. Transpl Int; 2010 Jan;23(1):101-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of residual Hodgkin's disease demonstrated by PET/CT in a deceased organ donor.
  • With the current limited availability of organs for transplantation, it is important to consider marginal donor candidates, including survivors of potentially curable malignancies such as lymphoma.
  • The absence of refractory/recurrent residual disease at the time of brain death can be difficult to establish.
  • We report a unique situation in which (18)F-fluorodeoxyglucose positron emission tomography (PET) was used to rule out Hodgkin's lymphoma recurrence in a 33-year-old, heart-beating, brain-dead, potential donor with a past history of Hodgkin's disease and a persistent mediastinal mass.
  • We present a new means of evaluating potential brain-dead donors with a past history of some lymphoma, whereby PET may help transplant physicians by optimizing donation safety while rationalizing the inclusion of marginal donors.
  • [MeSH-major] Hodgkin Disease / pathology. Neoplasm, Residual / pathology. Positron-Emission Tomography. Tissue Donors. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Brain Death / pathology. Female. Fluorodeoxyglucose F18. Humans. Radiopharmaceuticals. Tissue and Organ Procurement / methods. Tissue and Organ Procurement / standards

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19682299.001).
  • [ISSN] 1432-2277
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


9. Roh JL, Huh J, Suh C: Primary non-Hodgkin's lymphomas of the major salivary glands. J Surg Oncol; 2008 Jan 1;97(1):35-9
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphomas of the major salivary glands.
  • METHODS: We retrospectively assessed 20 patients with previously untreated non-Hodgkin's lymphomas (NHLs) and histologically confirmed as having parenchymal involvement of the salivary glands.
  • RESULTS: At diagnosis, the 12 patients with MALT lymphoma had a greater mean age and longer duration than did the 8 patients with other NHLs (P < 0.05).
  • Eight of the 12 MALT lymphoma patients had recurrent episodes of salivary gland swelling and 5 had myoepithelial sialadenitis, Sjögren syndrome, or gastric MALT lymphoma; these were not observed in the 8 other NHL patients.
  • Compared with the latter group, the MALT lymphoma group had significantly greater five-year relapse-free (37.5% vs. 91.7%, P < 0.05) and disease-free (35.0% vs. 90.9%, P < 0.05) survival rates.
  • However, two MALT lymphoma patients with high-grade transformation had recurrences beyond the head and neck region.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Lymphoma, B-Cell, Marginal Zone / mortality. Lymphoma, B-Cell, Marginal Zone / pathology. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17929252.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Jabbour E, Peslin N, Arnaud P, Ferme C, Carde P, Vantelon JM, Bocaccio C, Bourhis JH, Koscielny S, Ribrag V: Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation. Leuk Lymphoma; 2005 Jun;46(6):861-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
  • High-dose therapy (HDT) is now recommended for patients under 60 years of age with chemosensitive relapsed aggressive non-Hodgkin's lymphoma.
  • Prognostic factors are needed to predict which patients with chemosensitive lymphoma to second-line therapy could benefit from HDT.
  • We retrospectively investigated the prognostic value of the widely used age-adjusted International Prognostic Index (AA-IPI) calculated at the time of relapse (35 patients) or just before second-line salvage therapy for primary refractory disease (5 patients).
  • Thirty-six patients had diffuse large B-cell lymphoma.
  • Ten patients had an IPI >1, 16 had relapsed early (<6 months after first-line therapy) or disease was refractory to first-line therapy (5 of the 16 patients).
  • Overall survival was not statistically different in patients with refractory disease or in those who relapsed early compared with late failures (>6 months after first-line chemotherapy) (P=1), but the AA-IPI >1 was associated with a poor outcome (P=0.03).
  • In conclusion, the AA-IPI could have a prognostic value in patients with chemosensitive recurrent lymphoma treated with BEAM HDT.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Male. Medical Oncology / standards. Melphalan / therapeutic use. Middle Aged. Prednisolone / therapeutic use. Prognosis. Recurrence. Remission Induction. Transplantation, Autologous. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019530.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen; VAP-cyclo protocol
  •  go-up   go-down


11. Bucerius J, Herkel C, Joe AY, Altehoefer C, Finke J, Moser E, Reinhardt MJ: (18)F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma. An analysis of 193 patient studies. Nuklearmedizin; 2006;45(3):105-10; quiz N25-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (18)F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma. An analysis of 193 patient studies.
  • The AIM of this study was to assess the diagnostic value of FDG-PET and conventional imaging (CI) in a large series of patient with Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) at three time points during their course of disease.
  • PATIENTS, METHODS: 169 consecutive lymphoma patients (69 HD; 100 NHL) were included.
  • Differences in staging and diagnosis of residual or recurrent lymphoma were compared.
  • CONCLUSION: FDG-PET should be considered as the diagnostic modality of choice for post-therapeutic assessment of lymphoma patients and may be a reliable alternative to CI for staging at baseline and diagnosis of recurrence.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Recurrence. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710505.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] eng; ger
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ: Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res; 2007 Oct 15;13(20):6168-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
  • EXPERIMENTAL DESIGN: Patients with relapsed/refractory CD20+ B cell non-Hodgkin's lymphoma received i.v. rituximab (375 mg/m2/week for 4 weeks) and PF-3512676 weekly for 4 weeks either i.v. (0.04, 0.16, 0.32, or 0.48 mg/kg) or s.c. (0.01, 0.04, 0.08, or 0.16 mg/kg).
  • Objective responses occurred in 12 of 50 (24%) patients overall and in 6 of 12 (50%) patients in the extended-treatment cohort, including 2 patients with rituximab-refractory disease.
  • CONCLUSION: Brief or extended-duration PF-3512676 can be safely administered in combination with rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Lymphoma, Non-Hodgkin / drug therapy. Oligodeoxyribonucleotides / administration & dosage. Toll-Like Receptors / agonists
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / biosynthesis. Cohort Studies. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Recurrence. Rituximab. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947483.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Oligodeoxyribonucleotides; 0 / ProMune; 0 / Toll-Like Receptors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


13. Luthy SK, Ng AK, Silver B, Degnan KO, Fisher DC, Freedman AS, Mauch PM: Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma. Ann Oncol; 2008 Dec;19(12):2043-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: Thirty-three patients with advanced or recurrent indolent non-Hodgkin's lymphoma (NHL) received LD-IF-RT to 43 sites.
  • Thirty-six sites (84%) had a complete response (CR), five sites (12%) had a partial response, and two sites (5%) had progressive disease.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Feb 15;83(4):881-4 [8111061.001]
  • [Cites] Hematol Oncol. 1994 Jan-Feb;12(1):1-8 [8194839.001]
  • [Cites] Br J Cancer. 1994 Jun;69(6):1088-93 [8198975.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1282-90 [8648385.001]
  • [Cites] Radiother Oncol. 1997 Jan;42(1):49-51 [9132826.001]
  • [Cites] Eur J Cancer. 2005 Aug;41(12):1724-30 [16039113.001]
  • [Cites] Curr Probl Cancer. 1987 Nov-Dec;11(6):363-447 [3125008.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):928-34 [16243446.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2426-33 [17485708.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):148-55 [11516864.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1219-27 [11728680.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1466-70 [12459371.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2474-80 [12829665.001]
  • [Cites] Hematol Oncol. 2005 Mar;23(1):10-7 [16158458.001]
  • (PMID = 18647962.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2733122
  •  go-up   go-down


14. Campbell B, Wirth A, Milner A, Di Iulio J, MacManus M, Ryan G: Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure. Int J Radiat Oncol Biol Phys; 2005 Dec 1;63(5):1538-45
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.
  • PURPOSE: To evaluate the long-term results of salvage radiotherapy (SRT) for Hodgkin's lymphoma after chemotherapy failure.
  • METHODS AND MATERIALS: We reviewed 81 patients undergoing SRT for persistent or recurrent Hodgkin's lymphoma after chemotherapy; 19 also received conventional-dose salvage chemotherapy.
  • Of the 81 patients, 81% had Stage I-II, 25.9% had B symptoms, 14.8% had bulky disease, and 7.4% had extranodal disease.
  • The adverse prognostic factors for freedom from treatment failure were age >50 years (p < 0.001), B symptoms (p < 0.001), extranodal disease (p = 0.012), and less than a CR to the last chemotherapy regimen (p = 0.001).
  • CONCLUSIONS: Salvage radiotherapy is effective for selected patients with Hodgkin's lymphoma after chemotherapy failure and should be considered for incorporation into salvage programs.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Child, Preschool. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Recurrence. Sex Factors. Treatment Failure. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125872.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


15. Petropoulos D, Worth LL, Mullen CA, Lockhart S, Choroszy M, Chan KW: Interferon-alpha after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma. Bone Marrow Transplant; 2006 Sep;38(5):345-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma.
  • Thirteen children with refractory or recurrent Hodgkin's lymphoma (HL) received high-dose chemotherapy and autologous hematopoietic stem cell transplant (ASCT).
  • One patient relapsed.
  • Three patients were not treated with IFN-alpha initially, two because of rapidly progressive disease.
  • [MeSH-major] Hodgkin Disease / therapy. Interferon-alpha / therapeutic use. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Recurrence. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16915224.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


16. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE: Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol; 2005 Apr 1;23(10):2240-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
  • PURPOSE: We investigated the efficacy and safety of administering high-dose rituximab (HD-R) in combination with high-dose carmustine, cytarabine, etoposide, and melphalan chemotherapy and autologous stem-cell transplantation (SCT) in patients with recurrent B-cell aggressive non-Hodgkin's lymphoma (NHL).
  • HD-R of 1,000 mg/m(2) was administered again days 1 and 8 after transplantation.
  • Disease-free survival was 67% (95% CI, 51% to 79%) for the study group and 43% (95% CI, 26% to 60%) for the control group (P = .004).
  • CONCLUSION: The results of this study suggest that using HD-R and autologous SCT is a feasible and promising treatment for patients with B-cell aggressive NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Carmustine / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Infusions, Intravenous. Injections, Subcutaneous. Male. Melphalan / administration & dosage. Middle Aged. Rituximab. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800314.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


17. Robak T, Lech-Maranda E, Janus A, Blonski J, Wierzbowska A, Gora-Tybor J: Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. Leuk Lymphoma; 2007 Jun;48(6):1092-101
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
  • The aim of this study was to determine the feasibility, efficacy and toxicity of the combined therapy consisting of cladribine (2-CdA), mitoxantrone and cyclophosphamide (CMC regimen) in patients with refractory or relapsed non-Hodgkin's lymphoma (NHL).
  • Thirty six patients, 14 with mantle cell lymphoma (MCL), 10 with diffuse large B-cell lymphoma (DLBCL), 5 with follicular lymphoma (FL), 3 with small lymphocytic lymphoma (SLL), and 4 with T-cell lymphoma were enrolled to the study.
  • When different disease status before CMC treatment was considered, a trend toward longer survival of recurrent patients was observed (log rank test, P = 0.08).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cladribine / adverse effects. Cladribine / therapeutic use. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Feasibility Studies. Female. Humans. Male. Middle Aged. Mitoxantrone / adverse effects. Mitoxantrone / therapeutic use. Salvage Therapy / adverse effects. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577772.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; CMC protocol 2
  •  go-up   go-down


18. Ellis AK, Waserman S: Hodgkin's lymphoma presenting with markedly elevated IgE: a case report. Allergy Asthma Clin Immunol; 2009 Dec;5(1):12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma presenting with markedly elevated IgE: a case report.
  • CASE PRESENTATION: We present the case of a 22 year old female referred to the adult Allergy & Clinical Immunology clinic for an extremely elevated IgE level, eventually diagnosed with Hodgkin's lymphoma.
  • She had no history of atopy, recurrent infections, eczema or periodontal disease; stool was negative for ova & parasites.
  • Mediastinal lymph node biopsy was consistent with Hodgkin's lymphoma, nodular sclerosing subtype, grade I/II.
  • CONCLUSION: Although uncommon, markedly elevated IgE may be a manifestation of a malignant process, most notably both Hodgkin's and Non-Hodgkin's lymphomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2521-5 [15621772.001]
  • [Cites] Intern Med. 1997 Jun;36(6):420-3 [9213190.001]
  • [Cites] Int Arch Allergy Immunol. 1997 Apr;112(4):415-21 [9104800.001]
  • [Cites] Ann Allergy Asthma Immunol. 1997 Jan;78(1):27-8 [9012616.001]
  • [Cites] Int Arch Allergy Appl Immunol. 1985;76(3):282-5 [3156095.001]
  • [Cites] Blood. 1992 Mar 15;79(6):1518-22 [1532136.001]
  • [Cites] J Allergy Clin Immunol. 1989 Jan;83(1):5-10 [2783597.001]
  • [Cites] J Clin Invest. 1985 Jun;75(6):1977-82 [3159754.001]
  • [Cites] Dermatology. 1996;192(2):110-5 [8829490.001]
  • (PMID = 20016775.001).
  • [ISSN] 1710-1492
  • [Journal-full-title] Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
  • [ISO-abbreviation] Allergy Asthma Clin Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2794847
  •  go-up   go-down


19. Chamberlain MC, Johnston SK, Van Horn A, Glantz MJ: Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol; 2009 Feb;91(3):271-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C.
  • BACKGROUND: The most frequent central nervous system complication of systemic non-Hodgkin's lymphoma (NHL) is lymphomatous meningitis (LM).
  • OBJECTIVE: A clinical series to test the feasibility of combining intra-CSF liposomal ara-C and rituximab for the treatment of recurrent LM.
  • RESULTS: Fourteen patients with recurrent, cytologically positive lymphomatous meningitis were treated.
  • Best response to treatment included 10 partial responses and four with progressive disease.
  • Cause of death was progressive neurological disease in 7, systemic disease in 1, and combined systemic and neurological disease in 2 patients.
  • CONCLUSIONS: The combination of intra-CSF liposomal ara-C and rituximab administered in this schedule appears to have no additive toxicity and has modest palliative activity in patients with recurrent LM.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Cytarabine / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Meningitis / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy / methods. Drug Administration Routes. Drug Delivery Systems. Female. Follow-Up Studies. Humans. Male. Middle Aged. Phospholipids / therapeutic use. Rituximab. Survival Analysis

  • MedlinePlus Health Information. consumer health - Meningitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18820836.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Phospholipids; 0 / liposom; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


20. Jogai S, Al-Jassar A, Dey P, Adesina AO, Amanguno HG, Francis IM: Fine needle aspiration cytology of Hodgkin's lymphoma: A cytohistologic correlation study from a cancer center in Kuwait. Acta Cytol; 2006 Nov-Dec;50(6):656-62
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of Hodgkin's lymphoma: A cytohistologic correlation study from a cancer center in Kuwait.
  • OBJECTIVE: To assess the diagnostic accuracy offine needle aspiration cytology (FNAC) in the diagnosis of Hodgkin's lymphoma (HL).
  • Of these, 42 were correctly diagnosed as HL, and there was a discorrelation in 4 cases, comprising 3 cases of non-HL (T-cell-rich B-cell lymphoma [TCRBCL]-2, anaplastic large cell lymphoma-1) and 1 case of metastatic carcinoma.
  • CONCLUSION: FNAC is very useful for rapid and accurate approach to the diagnosis of recurrent and most cases of primary HL.
  • Because of morphologic similarities, it is difficult to differentiate HL from anaplastic large cell lymphoma and TCRBCL on FNAC.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Cancer Care Facilities. Child. Child, Preschool. Diagnosis, Differential. Diagnostic Errors. Female. Follow-Up Studies. Humans. Immunohistochemistry. Kuwait. Lymphoma, B-Cell / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Male. Middle Aged. Reproducibility of Results. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152278.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Weng WK, Negrin RS, Lavori P, Horning SJ: Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol; 2010 Jan 10;28(2):279-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.
  • PURPOSE: Rituximab has been given after autologous hematopoietic cell transplantation for recurrent or refractory B-cell lymphoma with the goal of eradicating minimal residual disease.
  • In the current report, we determine whether FcgammaR polymorphisms are correlated with clinical outcomes in 33 patients with B-cell non-Hodgkin's lymphoma who received post-transplantation rituximab.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2000;6(6):628-32 [11128813.001]
  • [Cites] Leuk Lymphoma. 2009 Sep;50(9):1494-500 [19672774.001]
  • [Cites] Leuk Res. 2002 Jun;26(6):597-600 [12007508.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(10):544-9 [12434949.001]
  • [Cites] Arthritis Rheum. 2003 Feb;48(2):455-9 [12571855.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 1:i21-7 [12736227.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):913-8 [12786803.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2691-4; discussion 2691-4 [12826650.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):457-64 [12877674.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Blood. 2004 Feb 1;103(3):777-83 [12907446.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1472-4 [14563637.001]
  • [Cites] Haematologica. 2004 Mar;89(3):361-3 [15020279.001]
  • [Cites] Bone Marrow Transplant. 2004 May;33(9):921-3 [15034544.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4028-35 [14976055.001]
  • [Cites] J Immunol. 1987 Feb 1;138(3):765-74 [3100615.001]
  • [Cites] Blood. 1993 Aug 1;82(3):931-9 [7687898.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3334-41 [7538824.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):474-81 [15659493.001]
  • [Cites] J Exp Med. 2005 Jun 6;201(11):1771-80 [15939792.001]
  • [Cites] Blood. 2005 Aug 1;106(3):795-802 [15718416.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10 [16537476.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 4:iv31-2 [16702182.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Leuk Lymphoma. 2006 Jun;47(6):965-6 [16840184.001]
  • [Cites] Leuk Lymphoma. 2006 Jun;47(6):1013-7 [16840190.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2720-5 [16609067.001]
  • [Cites] Int J Hematol. 2006 Oct;84(3):242-7 [17050199.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]
  • [Cites] Blood. 2007 Feb 1;109(3):951-3 [17032925.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):364-9 [17079695.001]
  • [Cites] Haematologica. 2007 Feb;92(2):e20-3 [17405749.001]
  • [Cites] Haematologica. 2007 Jul;92(7):998-9 [17606457.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1127-30 [17650444.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3712-8 [17704420.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8882-90 [17875730.001]
  • [Cites] Br J Dermatol. 2007 Dec;157(6):1271-3 [17916218.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1789-96 [18347005.001]
  • [Cites] Ann Rheum Dis. 2008 Jun;67(6):893-4 [18474658.001]
  • [Cites] Leuk Lymphoma. 2009 Mar;50(3):357-65 [19263297.001]
  • [Cites] Blood. 2009 Apr 16;113(16):3765-72 [19029438.001]
  • [Cites] Leuk Lymphoma. 2009 May;50(5):723-7 [19452316.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • (PMID = 19933905.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA111827; United States / NCI NIH HHS / CA / P01 CA049605; United States / NCI NIH HHS / CA / CA111827
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / FCGR3A protein, human; 0 / Receptors, IgG; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2815716
  •  go-up   go-down


22. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M: Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol; 2007 Apr 10;25(11):1350-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.
  • Systemic rituximab does not reduce the risk of CNS relapse or dissemination in patients with large cell lymphoma.
  • We therefore conducted a phase I dose-escalation study of intrathecal rituximab monotherapy in patients with recurrent CNS non-Hodgkin's lymphoma (NHL).
  • High RNA levels of Pim-2 and FoxP1 in meningeal lymphoma cells were associated with disease refractory to rituximab monotherapy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Central Nervous System Neoplasms / drug therapy. Eye Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Dose-Response Relationship, Drug. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Oct 1;25(28):4508-9; author reply 4509-11 [17906219.001]
  • (PMID = 17312328.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR-00079; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / R01 CA101042-01
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


23. Heyning FH, Jansen PM, Hogendoorn PC, Szuhai K: Array-based comparative genomic hybridisation analysis reveals recurrent chromosomal alterations in primary diffuse large B cell lymphoma of bone. J Clin Pathol; 2010 Dec;63(12):1095-100
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array-based comparative genomic hybridisation analysis reveals recurrent chromosomal alterations in primary diffuse large B cell lymphoma of bone.
  • AIMS: Primary non-Hodgkin's lymphoma of bone (PLB) is a rare subtype of primary extranodal diffuse large B cell lymphoma.
  • Here the authors performed the first array-CGH study to detect illness related genomic alterations in nine, clinically well-staged primary lymphoma of bone cases.
  • METHODS: Nine frozen samples from primary lymphoma of bone patients were immunophenotyped and subsequently investigated using a well-established array-CGH platform.
  • RESULTS: Of the nine patients, eight reached complete remission, and one had progressive disease and died of primary lymphoma of bone.
  • CONCLUSIONS: The authors found several recurrent genomic aberrations, including five cases with gain of 1q and four cases with 2p16.1 amplification.
  • These findings further substantiate the notion that primary lymphoma of bone should be considered as a distinct entity not only on clinic-pathological grounds but also on the genomic level as well.
  • [MeSH-major] Bone Neoplasms / genetics. Chromosome Aberrations. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Comparative Genomic Hybridization / methods. Cryopreservation. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oligonucleotide Array Sequence Analysis / methods. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20962053.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Buhmann R, Simoes B, Stanglmaier M, Yang T, Faltin M, Bund D, Lindhofer H, Kolb HJ: Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant; 2009 Mar;43(5):383-97
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion.
  • Donor lymphocyte infusions (DLIs) after allo-SCT displayed limited use in CLL and highly malignant non-Hodgkin's lymphoma (NHL).
  • Here we studied whether Bi20 (FBTA05), a novel trifunctional bispecific antibody targeting CD20 on lymphoma cells and CD3 on T cells, could induce GVL responses in combination with DLI or mobilized PBSCT after allogeneic transplantation in these diseases.
  • [MeSH-major] Adoptive Transfer. Antibodies, Bispecific / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Female. Graft vs Host Disease / etiology. Humans. Male. Middle Aged. Pilot Projects. Recurrence. Tissue Donors. Transplantation, Homologous

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18850012.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Bi20 antibody
  •  go-up   go-down


25. Aqel RA, Lloyd SG, Gupta H, Zoghbi GJ: Three-vessel coronary artery disease, aortic stenosis, and constrictive pericarditis 27 years after chest radiation therapy: a case report. Heart Surg Forum; 2006;9(4):E728-30
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-vessel coronary artery disease, aortic stenosis, and constrictive pericarditis 27 years after chest radiation therapy: a case report.
  • A patient with a history of Hodgkin's lymphoma presented with recurrent left pleural effusions and dyspnea on exertion 27 years after radiation therapy.
  • Further evaluation disclosed suspected radiation-induced constrictive pericarditis, aortic stenosis and regurgitation, and severe coronary artery disease.
  • [MeSH-major] Aortic Valve Stenosis / etiology. Coronary Artery Disease / etiology. Pericarditis, Constrictive / etiology. Radiation Injuries / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Humans. Longitudinal Studies. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844629.001).
  • [ISSN] 1522-6662
  • [Journal-full-title] The heart surgery forum
  • [ISO-abbreviation] Heart Surg Forum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Rebours V, Lévy P, Hammel P, Farges O, Ruszniewski P: [Cholangiocarcinoma due to postradiation therapy cholangitis and chronic pancreatitis]. Gastroenterol Clin Biol; 2005 Jun-Jul;29(6-7):732-4
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a 40 year old patient who had undergone thoracoabdominal radiotherapy for Hodgkin's disease, 22 years ago.
  • Recurrent angiocholangitis led us to schedule a biliodigestive anastomosis.
  • [MeSH-minor] Adult. Chronic Disease. Humans. Male

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142009.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


27. Eric Searls D, Sico JJ, Bulent Omay S, Bannykh S, Kuohung V, Baehring J: Unusual presentations of nervous system infection by Cryptococcus neoformans. Clin Neurol Neurosurg; 2009 Sep;111(7):638-42
Hazardous Substances Data Bank. WARFARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurological manifestations of C. neoformans infection include meningitis and, less commonly, parenchymal CNS granulomatous disease.
  • A patient with Hodgkin's disease was diagnosed with cryptococcal meningitis and dermatitis mimicking ophthalmic zoster.
  • An immunocompetent patient presented with recurrent cerebral infarctions in the setting of cryptococcal meningitis.
  • [MeSH-minor] Abscess / complications. Abscess / microbiology. Abscess / pathology. Adult. Aged. Amphotericin B / therapeutic use. Anticoagulants / administration & dosage. Anticoagulants / adverse effects. Anticoagulants / therapeutic use. Antifungal Agents / therapeutic use. Brain / microbiology. Brain / pathology. HIV Infections / complications. Hodgkin Disease / complications. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Spinal Diseases / microbiology. Spinal Diseases / pathology. Tomography, X-Ray Computed. Warfarin / administration & dosage. Warfarin / adverse effects. Warfarin / therapeutic use

  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19541406.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antifungal Agents; 5Q7ZVV76EI / Warfarin; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


28. Achemlal L, Mikdame M, Nouijai A, Bezza A, El Maghraoui A: Dramatical improvement of chemoresistant bone lymphoma with rituximab. Clin Rheumatol; 2006 May;25(3):394-5
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatical improvement of chemoresistant bone lymphoma with rituximab.
  • Non-Hodgkin's lymphoma of the bone is a very rare disease that accounts for approximately 5% of all extranodal non-Hodgkin's lymphomas and for 7-10% of primary bone tumours.
  • Biopsy revealed diffuse, large B-cell non-Hodgkin's lymphoma expressing CD20.
  • His arm pain worsened, and x-rays demonstrated progressive disease.
  • Radiographic studies conducted 3 months after rituximab therapy showed marked improvement in his humerus disease.
  • He had no evidence of recurrent lymphoma 24 months later.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Bone Neoplasms / diagnosis. Drug Resistance, Neoplasm. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Humans. Humerus / pathology. Humerus / radiography. Male. Remission Induction. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247586.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


29. Mohammadianpanah M, Omidvai S, Mosalei A, Ahmadloo N: Treatment results of tonsillar lymphoma: a 10-year experience. Ann Hematol; 2005 Apr;84(4):223-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of tonsillar lymphoma: a 10-year experience.
  • Primary extranodal non-Hodgkin's lymphomas of the head and neck account for 10-20% of all non-Hodgkin's lymphomas.
  • Primary tonsillar lymphoma accounts for less than 1% of head and neck malignancies, although the tonsil is the most common primary extranodal site of head and neck non-Hodgkin's lymphomas.
  • In this study we analyzed our cases of tonsillar lymphoma treated in our institution during the last 10 years to compare the finding of this study with those of previous studies.
  • We reviewed the cases of tonsillar lymphoma treated in the Radiation Oncology Department of Shiraz University from 1992 to 2002.
  • Between 1992 and 2002, 19 patients with stage IE (10), IIE (7), and IIIE (2) disease were treated.
  • A late fatal side effect was observed in one patient who developed radiation-induced sarcoma 7 years after initial diagnosis and died 8 months later without evidence of recurrent lymphoma.
  • Age, sex, stage, bulk of disease, performance status, number of chemotherapy cycles, number of involved sites, histologic subtypes, and radiation dose were analyzed as prognostically significant for disease-specific survival in our cases.
  • Combined chemotherapy and radiation therapy is safe, highly effective, and probably curative for most patients with primary tonsillar lymphoma.
  • [MeSH-major] Combined Modality Therapy / methods. Lymphoma, Non-Hodgkin / therapy. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Follow-Up Studies. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant / adverse effects. Remission Induction / methods. Retrospective Studies. Risk Factors. Survival Rate. Tonsillectomy. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15042316.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Piura B, Rabinovich A, Shaco-Levy R, Sukenik S: Vulvar invasive squamous cell carcinoma occurring in a young woman with systemic lupus erythematosus. Eur J Gynaecol Oncol; 2005;26(1):103-5
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although several studies have demonstrated a possible relationship between systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemia and several solid tumors, it is still debatable whether SLE patients have an increased incidence of cancer overall.
  • The patient underwent radical vulvectomy and bilateral groin sentinel lymph node dissection and until to date, one year after surgery, she is alive without evidence of recurrent disease.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Neoplasm Invasiveness


31. Graham BB, Mathisen DJ, Mark EJ, Takvorian RW: Primary pulmonary lymphoma. Ann Thorac Surg; 2005 Oct;80(4):1248-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary lymphoma.
  • BACKGROUND: Primary pulmonary lymphoma is a rare disease.
  • METHODS: A retrospective review of primary pulmonary lymphoma cases at a single institution from 1990 to 2002 was performed.
  • Fourteen patients had mucosa-associated lymphoid tissue (MALT) lymphoma, 2 had large cell transformation of sheet cells in MALT lymphoma, and 1 each had Hodgkin's disease and follicular lymphoma.
  • Eleven patients had disease confined to the pulmonary parenchyma, and 7 had parenchymal disease as well as mediastinal lymphadenopathy.
  • Kaplan-Meier estimate of median time to disease recurrence or death was 6 years.
  • Only 1 patient died of disease-related causes.
  • Patients who had bilateral disease were more likely to have recurrent disease or death (p = 0.03).
  • CONCLUSIONS: A wide range of treatments were used for patients with generally MALT lymphoma, resulting in good outcomes, and recurrent disease was well controlled.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Lymphoma / diagnosis. Lymphoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Hodgkin Disease / pathology. Hodgkin Disease / radiography. Hodgkin Disease / surgery. Humans. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / radiography. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Follicular / pathology. Lymphoma, Follicular / radiography. Lymphoma, Follicular / surgery. Male. Middle Aged. Neoplasm Staging / methods. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181848.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


32. Kumpulainen EJ, Hirvikoski PP, Johansson RT: Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer. Acta Oncol; 2008;47(1):120-3
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred and ninety four patients, 185 primary early breast cancer and nine locoregionally recurrent breast cancer patients, were entered onto the trial between May 1986 and November 1993.
  • Eighty nine (48%) primary breast cancers relapsed, and six locoregional breast cancers relapsed.
  • Two cases of leukemia, six cases of skin cancer, two cases of Hodgkin's disease, two cases of meningioma, and two cases of endometrial cancer were observed.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Disease-Free Survival. Feasibility Studies. Female. Fluorouracil / administration & dosage. Humans. Methotrexate / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097780.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


33. Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, Battista G, Tani M, Stefoni V, Canini R, Monetti N, Rubello D, Alavi A, Franchi R, Fanti S: 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging; 2005 Jul;32(7):749-56
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET in malignant lymphoma: significance of positive findings.
  • PURPOSE: The aim of this study was to evaluate the significance of increased uptake of 18F-fluorodeoxyglucose (FDG) in patients with malignant lymphoma (ML) studied by positron emission tomography (PET).
  • METHODS: A total of 1,120 consecutive scans carried out in 848 patients were reviewed; all patients had a diagnosis of ML [574 non-Hodgkin's lymphoma (NHL) and 274 Hodgkin's disease (HD)] and were studied at completion of therapy, for suspected recurrence or during follow-up.
  • PET findings were considered positive for lymphomatous localisation when uptake occurred at sites of previous disease, in asymmetrical lymph nodes or in nodes unlikely to be affected by inflammation (mediastinal, except for hilar, and abdominal).
  • PET findings were adjudged negative for neoplastic localisations in the following instances: physiological uptake (urinary, muscular, thymic or gastrointestinal in patients without MALT), symmetrical nodal uptake, uptake in lesions unrelated to lymphoma that had already been identified by other imaging methods at the time of PET scan, uptake at sites atypical for lymphoma, very low uptake and non-focal uptake.
  • RESULTS: Overall, 354 scans (in 256 patients) showed increased FDG uptake (244 scans in NHL and 110 in HD): in 286 cases, FDG uptake was considered pathological and indicative of ML, in 41 cases the findings were described as uncertain or equivocal and in 37 cases, FDG uptake was considered unrelated to ML (in ten scans, concurrent findings of abnormal FDG uptake attributed to ML and uptake assigned to other causes were obtained) .
  • Of the 286 patients with positive PET findings, 274 (95.8%) were found to have residual or recurrent ML (i.e. true positives).
  • As already suggested, increased FDG uptake may also be observed in patients without active disease; in most cases, however, non-pathological FDG accumulation is properly identified.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Lymphoma / diagnosis. Lymphoma / pathology. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. False Positive Reactions. Female. Humans. Image Processing, Computer-Assisted. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15785956.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


34. Oluwasanmi AF, Wood SJ, Baldwin DL, Sipaul F: Malignancy in asymmetrical but otherwise normal palatine tonsils. Ear Nose Throat J; 2006 Oct;85(10):661-3
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient had high-grade non-Hodgkin's lymphoma in the larger tonsil, and the other had lymphocyte-rich Hodgkin's lymphoma.
  • Both patients were older than 50 years, and neither had a history of recurrent tonsillitis.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Palatine Tonsil / pathology. Tonsillar Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Fatal Outcome. Female. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Risk Factors. Tonsillectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124938.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Biswas T, Dhakal S, Chen R, Hyrien O, Bernstein S, Friedberg JW, Fisher RI, Liesveld J, Phillips G, Constine LS: Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol Biol Phys; 2010 May 1;77(1):79-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.
  • PURPOSE: For patients with recurrent or refractory large B-cell non-Hodgkin's lymphoma, high-dose chemotherapy and autologous stem cell transplant (ASCT) is the treatment of choice.
  • MATERIALS AND METHODS: Between May 1992 and April 2005, 176 patients underwent ASCT for recurrent or refractory large B-cell non-Hodgkin's lymphoma; 164 patients were evaluable for endpoint analysis.
  • RESULTS: The 5-year overall survival (OS) and disease-specific survival (DSS) improved with IFRT in both the R-CHOP (p = 0.006 and 0.02, respectively) and CHOP (p = 0.02 and p = 0.04, respectively) groups.
  • CONCLUSIONS: Recognizing that positive and negative patient selection bias exists for the use of IFRT post-ASCT, patients initially treated with CHOP or R-CHOP and who undergo ASCT for recurrent or refractory disease may benefit from subsequent IFRT presumably due to enhanced local control that can translate into a survival advantage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Prednisone / administration & dosage. Remission Induction. Rituximab. Salvage Therapy / methods. Survival Analysis. Transplantation, Autologous. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647953.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


36. Yildiz F, Genc M, Akyurek S, Cengiz M, Ozyar E, Selek U, Atahan IL: Radiotherapy in the management of Kaposi's sarcoma: comparison of 8 Gy versus 6 Gy. J Natl Med Assoc; 2006 Jul;98(7):1136-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirteen (28%) patients received chemotherapy before radiotherapy and were referred due to recurrent or progressive disease or intolerance to chemotherapy.
  • Eight out of 47 patients (17%) had an underlying immunocompromised state, and one had a previous diagnosis of Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / immunology. Sarcoma, Kaposi / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hospitals, Teaching. Humans. Immunocompromised Host. Male. Middle Aged. Prospective Studies. Radiotherapy Dosage. Treatment Outcome. Turkey

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):632-9 [15472910.001]
  • [Cites] Int J Oncol. 1999 Jun;14(6):1097-102 [10339664.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5C):4539-44 [10650807.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Dermatology. 2001;202(2):119-22 [11306832.001]
  • [Cites] Cancer. 1978 May;41(5):1733-8 [417796.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):684-7 [6766794.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):640-4 [6784910.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Nov;12(11):1931-5 [3771313.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Nov;12(11):2029-32 [3095276.001]
  • [Cites] Semin Oncol. 1987 Jun;14(2 Suppl 3):19-22 [2440108.001]
  • [Cites] Dermatologica. 1990;180(1):13-7 [2307273.001]
  • [Cites] J Am Acad Dermatol. 1990 Jun;22(6 Pt 2):1237-50 [2193952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):569-75 [2211205.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):419-22 [1995526.001]
  • [Cites] Epidemiol Rev. 1991;13:178-99 [1765111.001]
  • [Cites] Am J Clin Oncol. 1992 Jun;15(3):200-6 [1590271.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1057-61 [8262827.001]
  • [Cites] Dermatology. 1994;188(3):182-7 [8186506.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1207-11 [7525519.001]
  • [Cites] Int J Dermatol. 1994 Nov;33(11):755-62 [7822076.001]
  • [Cites] J Am Acad Dermatol. 1995 Jun;32(6):1000-3 [7538517.001]
  • [Cites] Dermatology. 1997;195(2):142-4 [9310721.001]
  • [Cites] Radiother Oncol. 1998 Jan;46(1):23-8 [9488123.001]
  • [Cites] J Virol. 1999 Feb;73(2):1438-46 [9882349.001]
  • [Cites] Radiother Oncol. 2005 Jul;76(1):59-62 [16019094.001]
  • (PMID = 16895284.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2569458
  •  go-up   go-down


37. Kim DH, Messner H, Minden M, Gupta V, Kuruvilla J, Wright J, Lipton J: Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis; 2008 Apr;10(2):90-8
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven patients (14%) received long-term prophylaxis of low-dose acyclovir (200 mg twice daily orally > or =3 months) for recurrent oral (n=21) or genital herpes simplex virus infection (n=5) or for a previous history of recurrent VZV infection (n=1).
  • A higher risk factor for VZV infection was pre-transplant diagnosis of a lymphoproliferative disorder (LPD): chronic lymphocytic leukemia, Hodgkin's disease, or non-Hodgkin's lymphoma (P=0.021, 52.5% in LPD vs. 32.6% in non-LPD group).
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Lymphoproliferative Disorders / complications. Lymphoproliferative Disorders / diagnosis. Male. Middle Aged. Multivariate Analysis. Peripheral Blood Stem Cell Transplantation. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Herpes Simplex.
  • MedlinePlus Health Information. consumer health - Shingles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17605742.001).
  • [ISSN] 1399-3062
  • [Journal-full-title] Transplant infectious disease : an official journal of the Transplantation Society
  • [ISO-abbreviation] Transpl Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antiviral Agents; X4HES1O11F / Acyclovir
  •  go-up   go-down


38. Petrella F, Leo F, Veronesi G, Solli P, Borri A, Galetta D, Gasparri R, Lembo R, Radice D, Scanagatta P, Spaggiari L: "Salvage" surgery for primary mediastinal malignancies: is it worthwhile? J Thorac Oncol; 2008 Jan;3(1):53-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Mediastinal salvage surgery (MSS) was defined as surgical resection of persistent or recurrent primary mediastinal tumors after previous local treatments with curative intent or exclusive chemotherapy in case of bulky tumors.
  • Overall and disease-specific long-term survival was calculated.
  • Eleven patients suffered from thymic tumors (eight thymomas, three thymic carcinoma) whereas 10 patients suffered from nonthymic tumors (one lung adenocarcinoma + thymoma, two mediastinal monophasic sinovial sarcoma, one mediastinal neuroendocrine tumor, one mediastinal teratoblastoma, one mediastinal disgerminoma, one Hodgkin's lymphoma, one mediastinal atypic carcinoid, two medullary thyroid carcinoma).
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Dysgerminoma / pathology. Dysgerminoma / surgery. Female. Follow-Up Studies. Hodgkin Disease / pathology. Hodgkin Disease / surgery. Humans. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Male. Middle Aged. Morbidity. Mortality. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Retrospective Studies. Salvage Therapy / methods. Sarcoma / pathology. Sarcoma / surgery. Survival Analysis. Teratoma / pathology. Teratoma / surgery. Thymoma / pathology. Thymoma / surgery. Thymus Neoplasms / pathology. Thymus Neoplasms / surgery. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166841.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Manoukian G, Hagemeister F: Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther; 2009 Nov;9(11):1445-51
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In 1999, the FDA approved the use of denileukin diftitox for patients with persistent or relapsed CD25-positive cutaneous T-cell lymphoma (CTCL), but Ontak has been reported to be an effective therapy for other neoplastic and non-neoplastic conditions.
  • Oncological uses include therapy for CD25-negative T-cell lymphoma, recurrent and refractory chronic lymphocytic leukemia (CLL), non-Hodgkin's B-cell lymphoma (NHL), and human T-cell lymphotropic virus- 1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL).
  • Potential additional uses of Ontak include: therapy of graft-versus-host disease (GvHD) and autoimmune conditions, including psoriasis, rheumatoid arthritis (RA), systemic lupus, scleroderma and vasculitis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, T-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817678.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  • [Number-of-references] 37
  •  go-up   go-down


40. Radecke K, Frühauf NR, Miller M, Ross B, Köditz R, Malagó M, Broelsch CE, Gerken G, Treichel U: Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis. Liver Int; 2005 Feb;25(1):101-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The causes of graft failure were: recurrent thrombosis of the hepatic artery, HCV-associated cholestatic hepatitis and chemotherapy-induced liver damage due to Hodgkin's disease, which was diagnosed 17 months after OLT, in addition to chronic HCV disease.
  • CONCLUSIONS: A medium- or even long-term survival after OLT can be achieved in HIV-infected patients without progression of HIV disease under antiretroviral therapy.
  • [MeSH-minor] Adult. Female. Hepatitis, Viral, Human. Humans. Immunocompromised Host. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Prospective Studies. Survival Rate


41. Jameel A, Jamil SN: Safety of cytotoxic chemotherapy during pregnancy. J Pak Med Assoc; 2007 Sep;57(9):449-52
MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients (33%) had breast cancer, four (22%) had chronic myeloid leukaemia, two (11%) had Hodgkin's disease, two (11%) had acute myeloid leukaemia and one each had recurrent ovarian carcinoma (5.7%), soft-tissue sarcoma (5.7%), acute lymphoblastic leukaemia (5.7%) and non-Hodgkin's lymphoma (5.7%).
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Neoplasms / drug therapy. Pregnancy. Pregnancy Trimester, Second. Prospective Studies. Time Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18072640.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytotoxins
  •  go-up   go-down


42. Aleric I, Krpan M, Neralic-Meniga I: Unusual radiographic presentation of recurrent intrathoracic Hodgkin's disease. Wien Klin Wochenschr; 2006 Jul;118(13-14):389
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual radiographic presentation of recurrent intrathoracic Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / radiography. Neoplasm Recurrence, Local / radiography. Thoracic Neoplasms / radiography
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865642.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down






Advertisement